Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Peter Caravan
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Factor 1A, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Caravan is a co-founder of Factor 1A, LLC and holds equity in the private company. The company is developing fibrin binding technology for imaging probes. The research project aims to translate a recently developed fibrin-specific positron emission tomography (PET) probe for direct imaging of thrombus in patients and involves a peptide which is covered by a patent owned by Factor 1A, LLC. The results of this study could therefore be of interest to the company.
PET Imaging of Thrombus
Project Narrative Thrombosis (blood clot) is implicated in a number of diseases such as stroke, heart attack, and pulmonary embolism. We have developed a new positron emitting imaging probe that directly targets thrombus. Here we will evaluate its ability to detect blood clots in the hearts of patients with atrial fibrillation.
Filed on July 13, 2017.
Tell us what you know about Peter Caravan's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Peter Caravan filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | $150,000 - $199,999 |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Collagen Medical, LLC | $20,000 - $39,999 |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Collagen Medical, LLC | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.